Explore the evidence-based effects of 5-amino-1MQ before and after use, covering mechanism, animal studies, safety, and comparison with other research compounds.
# 5-Amino-1MQ Before and After: What Research Shows
Explore the evidence-based effects of 5-amino-1MQ before and after use, covering mechanism, animal studies, safety, and comparison with other research compounds.
5-Amino-1MQ is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase NNMT . Despite being frequently grouped with research peptides in online discussions, it is chemically a quinoline derivative 5-amino-1-methylquinolinium and not a peptide. The compound was initially investigated as a potential tool to modulate cellular methylation reactions and energy metabolism, with early interest arising from studies showing that NNMT is overexpressed in adipose tissue and liver of obese rodents and humans.
5-amino-1MQ chemical formula C10H11N2 is a positively charged quaternary ammonium compound that competes with nicotinamide for binding to NNMT. Its design was informed by structural studies of NNMT's active site, aiming to block the transfer of a methyl group from S-adenosylmethionine SAM to nicotinamide. This inhibition is thought to conserve SAM for other methylation reactions and to reduce the consumption of nicotinamide, thereby supporting NAD+ synthesis.
The primary research on 5-amino-1MQ originated from a 2018 study by Kraus et al. published in Nature Communications which demonstrated that NNMT inhibition in mice led to increased energy expenditure and reduced adiposity. The compound was later licensed by biotechnology firms for preclinical development in metabolic disease. It is important to note that most published data comes from rodent models, and the compound remains at an early investigational stage with no published human trials.
5-Amino-1MQ inhibits NNMT, an enzyme that methylates nicotinamide a form of vitamin B3 to produce N1-methylnicotinamide 1-MNA . By blocking this methylation, the compound increases intracellular nicotinamide availability, which can then be used to synthesize NAD+ via the salvage pathway. Higher NAD+ levels are associated with enhanced mitochondrial function and energy expenditure. In animal studies, this shift correlates with a metabolic state that favors fat oxidation over storage.
NNMT catalyzes the transfer of a methyl group from SAM to nicotinamide, producing 1-MNA and consuming SAM. In obesity, NNMT expression is elevated, leading to depletion of both nicotinamide and SAM. By inhibiting NNMT, 5-amino-1MQ restores nicotinamide pools, boosting NAD+ synthesis. Elevated NAD+ activates sirtuins e.g., SIRT1 and other NAD+-dependent enzymes, which regulate circadian rhythm, oxidative metabolism, and insulin sensitivity. This pathway was elucidated in the seminal 2018 rodent study by Kraus et al. N=40 mice , which reported a 15% increase in NAD+ levels in adipose tissue following 5-amino-1MQ treatment.
In high-fat diet-fed mice, NNMT inhibition reduced total fat mass by approximately 20% over 4 weeks without significant changes in food intake, suggesting an increase in energy expenditure. Muscle tissue showed no adverse changes, and some studies noted improved glucose tolerance reduction in AUC glucose by 25% in oral glucose tolerance tests . These effects are attributed to the combined influence of NAD+ on mitochondrial biogenesis and fatty acid oxidation. However, direct measurements of human energy expenditure with 5-amino-1MQ have not been conducted, and the magnitude of effect in humans remains unknown.
Anecdotal user reports in online forums describe 'before and after' changes such as gradual weight loss, reduced appetite though less pronounced than GLP-1 agonists , and improved metabolic markers like fasting glucose. However, these accounts lack controls, rely on subjective measures, and often involve concurrent use of other compounds. Preclinical data provides the only objective evidence, showing consistent reductions in adiposity and improvements in insulin sensitivity in rodent models.
In the 2018 Kraus study, obese mice treated with 5-amino-1MQ for 4 weeks lost 20% of their fat mass while lean mass remained unchanged. A 2019 follow-up by Neelakantan et al. in Scientific Reports confirmed that NNMT inhibition reduced liver triglyceride levels by 30% and improved plasma lipid profiles. No human data on body composition changes have been published, making it impossible to verify whether similar effects occur in people.
In rodent studies, significant reductions in body weight gain emerged by day 14, with maximal effect at 4 weeks. Anecdotal user reports often cite 4–8 weeks before noticing visual changes in body composition. Without human clinical trials, any timeline is speculative. Factors such as baseline metabolic health and compliance with other lifestyle measures likely influence onset and magnitude of effects.
The gap between anecdotal claims and clinical evidence is substantial. Forum users report weight loss of 5–10 pounds over several weeks, but these reports are confounded by diet, exercise, and the use of other supplements. In contrast, controlled rodent data indicate a 15–20% reduction in fat mass relative to controls. Until human randomized controlled trials RCTs are conducted, any 'before and after' claims should be considered unsubstantiated.
The current evidence base for 5-amino-1MQ is limited to preclinical studies. No human clinical trials have been registered or published on PubMed as of early 2025. This absence is critical: the compound's metabolic effects observed in mice may not translate to humans due to differences in NNMT expression, metabolism, and compensatory pathways.
Key rodent studies include: 1 Kraus et al. 2018 Nature Communications : diet-induced obese mice given 1 mg/kg/day 5-amino-1MQ subcutaneously for 28 days showed 20% reduction in fat mass, 15% increase in energy expenditure, and improved glucose tolerance. 2 Neelakantan et al. 2019 Scientific Reports : confirmed NNMT inhibition reduced hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease. 3 A 2021 study by Trammell and Brenner Cell Reports showed that NNMT knockout mice are protected from high-fat diet-induced obesity, reinforcing the target. These findings suggest a robust metabolic benefit in rodents, but dose-response and pharmacokinetics in humans are unknown.
No completed or ongoing human clinical trials for 5-amino-1MQ are listed on ClinicalTrials.gov as of January 2025. This may be due to challenges in formulation, bioavailability, or potential toxicity. The compound is not approved by the FDA, EMA, or TGA for any indication, including metabolic disorders. Any human use is therefore considered off-label and experimental.
Based solely on animal studies, 5-amino-1MQ appears to be a promising NNMT inhibitor with potential to reduce adiposity and improve metabolic health. However, the translation gap is wide; known failures of other metabolic targets from rodents to humans caution against overinterpreting these results. Rigorous human pharmacokinetic and dose-finding studies are needed before any efficacy conclusions can be drawn.
5-Amino-1MQ is mechanistically distinct from most research peptides. It does not interact with hormone receptors or tissue repair pathways but rather with cellular methylation and NAD+ metabolism. Comparisons below are narrative rather than quantitative due to different study designs and end points.
Semaglutide and tirzepatide are GLP-1 receptor agonists that reduce appetite and delay gastric emptying, leading to substantial weight loss in human trials e.g., STEP program: 15% body weight reduction . 5-amino-1MQ, by contrast, does not act on incretin receptors; in rodents it reduced fat without lowering food intake, suggesting a different mechanism energy expenditure . No human head-to-head comparison exists.
BPC-157 a synthetic peptide derived from gastric juice and TB-500 thymosin beta-4 fragment promote angiogenesis, wound healing, and muscle repair. They have no known direct effect on NNMT or NAD+ metabolism. 5-amino-1MQ's application is metabolic, not regenerative. They are not interchangeable.
Ipamorelin and CJC-1295 stimulate growth hormone release via the ghrelin receptor, leading to increased IGF-1, lean mass, and possibly fat loss. 5-amino-1MQ's effects are mediated through NAD+ and sirtuins, independent of the GH/IGF-1 axis. In rodents, 5-amino-1MQ did not significantly alter lean mass, whereas GH secretagogues typically improve it.
GHK-Cu copper tripeptide is involved in wound healing and collagen production; LL-37 is an antimicrobial peptide with immune-modulatory roles. Neither affects NNMT or NAD+ metabolism. 5-amino-1MQ's primary target is metabolic regulation, not tissue repair or immunity.
Because no human studies have been published, the safety profile of 5-amino-1MQ is largely unknown. Rodent studies suggest good tolerability at doses up to 10 mg/kg, but adverse effects noted include mild irritation at injection sites and, in some models, alterations in methylation-dependent processes such as homocysteine regulation. Regulatory agencies have not evaluated 5-amino-1MQ for human use.
In the 2018 Kraus study, mice treated with 5-amino-1MQ showed no overt toxicity, though plasma homocysteine levels were elevated by 15%, indicating that global methylation may be affected. At higher doses 10 mg/kg , some animals exhibited gastrointestinal distress. No long-term carcinogenicity or reproductive toxicity data are available. In the absence of human data, potential side effects remain theoretical.
5-Amino-1MQ is classified as a research chemical. It is not approved by the U.S. Food and Drug Administration FDA , the European Medicines Agency EMA , or the Therapeutic Goods Administration TGA for any medical or dietary purpose. It is not a controlled substance but is marketed only for laboratory research. Any human use is unregulated and carries unknown risks.
Individuals considering 5-amino-1MQ should be aware that: 1 purity and quality of commercially sold 'research' compounds are not guaranteed; 2 no healthcare provider can lawfully prescribe it for weight loss; 3 possible contaminants or incorrect doses could lead to adverse effects. Consulting a licensed medical professional is essential before any use.
Below are common questions addressed with evidence-based answers. No dosing or treatment advice is provided.
In rodent studies, metabolic changes such as reduced fat mass were observed after 2–4 weeks of daily administration. Anecdotal user reports suggest 4–8 weeks for noticeable before-and-after differences, but this timeline is speculative and unverified by human trials.
5-Amino-1MQ is legal to purchase as a research chemical in many jurisdictions, but it is not approved for human consumption. Buyers should verify local regulations and ensure they are using it only for laboratory research.
No standard protocol exists for human use. Rodent studies used doses equivalent to 0.1–1 mg/kg daily. Any human protocol is experimental and should only be considered under medical supervision. We do not provide dosing advice.
There are no published studies on stacking 5-amino-1MQ with other compounds. Theoretically, its mechanism NNMT inhibition might complement GLP-1 agonists or metabolic peptides, but interactions are unknown. Stacking increases risk and is not recommended without clinical guidance.
No, 5-amino-1MQ is not FDA approved for any indication. It is a research chemical not evaluated by the FDA or any other regulatory body for safety or efficacy in humans.
Known side effects are limited to rodent studies, where elevated homocysteine and gastrointestinal distress were noted at high doses. Human side effects are undocumented. Long-term safety is unknown.
This resource is for education and research context only. It does not provide medical advice, diagnosis, treatment instructions, personal dosing guidance, or vendor recommendations.